Comparative Effectiveness of Clopidogrel vs. Potent P2Y12 Inhibitors in CYP2C19 Normal Metabolizers Following Percutaneous Coronary Intervention: A Real-World Cohort Study.

Abstract excerpt

BACKGROUND: Evidence suggests that cytochrome P450 2C19 (CYP2C19) genotyping may guide clopidogrel therapy after percutaneous coronary intervention (PCI). However, evidence on the effectiveness of clopidogrel and potent P2Y12 inhibitors (ticagrelor or prasugrel) in patients with CYP2C19 normal metabolizer (NM) genotype remain limited. METHODS: This retrospective cohort study utilized nationwide genetic data from...

Topics

Join the communities discussing this publication.

• Clopidogrel
• Gastrointestinal Hemorrhage
• Hemorrhage
• Percutaneous Coronary Intervention